We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Renal Cell Carcinoma

Journal Scan / Research · January 04, 2022

CRP Flare–Response Predicts Efficacy of First-Line Anti–PD-1–Based Combination Therapy in Metastatic RCC

Clinical & Translational Immunology


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical & Translational Immunology
C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma
Clin Transl Immunology 2021 Dec 01;[EPub Ahead of Print], N Klümper, P Schmucker, O Hahn, B Höh, A Mattigk, S Banek, J Ellinger, J Heinzelbecker, D Sikic, M Eckstein, A Strauß, F Zengerling, M Hölzel, P Zeuschner, C Kalogirou

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading